Abstract Sjogren’s disease (SjD) is an autoimmune disease that is characterized not only by the sicca symptoms it causes but also by its systemic nature, which is capable of several and not yet fully understood extraglandular manifestations. To gain a clearer understanding of these manifestations as well as a better practical approach, a panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis on the identification of epidemiologic and clinical features of the extraglandular manifestations present in ESSDAI (EULAR Sjogren´s syndrome disease activity index), followed by a voting panel with recommendations for clinical practice. This publication is complementary to others already published and covers cutaneous and hematological manifestations, with prevalence data generated by a meta-analysis of 13 clinical or laboratory manifestations and 6 clinical management recommendations. Sjogrens Sjogren s SjD (SjD nature approach metaanalysis meta analysis EULAR index, index , index) practice 1

ABSTRACT Introduction: Cardiac surgery is a frequent surgical procedure and may present a high risk of complications. Among the prophylactic strategies studied to decrease the rates of negative outcomes, respiratory care seems to reduce pulmonary complications. Incentive spirometry (IS) is a low-cost, respiratory exercise technique, used for the prevention and treatment of postoperative pulmonary complications (PPC). The aim of this review was to evaluate whether IS is superior to respiratory care, mobilization exercises, and noninvasive ventilation on PPC, and clinical outcomes. Methods: Systematic review. Medical Literature Analysis and Retrieval System Online (or MEDLINE®), Embase®, Cochrane Central Register of Controlled Trials (or CENTRAL), Physiotherapy Evidence Database (or PEDro), Cumulative Index of Nursing and Allied Health (or CINAHL®), Latin American and Caribbean Health Sciences Literature (or LILACS), Scientific Electronic Library Online (or SciELO), Allied, Scopus®, and OpenGrey databases, clinical trial registration sites, conferences, congresses, and symposiums were searched. Results: Twenty-one randomized trials and one quasi-randomized trial (1,677 participants) were included. For partial pressure of oxygen (PaO2), IS was inferior to respiratory care (mean difference [MD] -4.48; 95% confidence interval [CI] -8.32 to -0.63). Flow-oriented IS was inferior to respiratory care on PaO2 (MD -4.53; 95% CI -8.88 to -0.18). However, compared to respiratory care, flow-oriented IS was superior on recovery vital capacity. Conclusions: This meta-analysis revealed that IS was not superior to standard respiratory care for PPCs and clinical outcomes, therefore its use should not be widely recommended until further studies with high quality be performed to ensure this clinical guidance. Introduction outcomes (IS lowcost, lowcost low cost, cost low-cost technique PPC. PPC . (PPC) exercises Methods or MEDLINE®, MEDLINE MEDLINE® , MEDLINE®) Embase Embase® CENTRAL, CENTRAL CENTRAL) PEDro, PEDro PEDro) CINAHL®, CINAHL CINAHL® CINAHL®) LILACS, LILACS LILACS) SciELO, SciELO SciELO) Scopus Scopus® databases sites conferences congresses searched Results Twentyone Twenty quasirandomized quasi 1,677 1677 1 677 (1,67 participants included PaO2, PaO (PaO2) mean MD [MD 4.48 448 4 48 -4.48 95 [CI 8.32 832 8 32 -8.3 0.63. 063 0.63 0 63 -0.63) Floworiented Flow oriented 4.53 453 53 -4.53 8.88 888 88 -8.8 0.18. 018 0.18 18 -0.18) However floworiented flow capacity Conclusions metaanalysis meta analysis guidance (PPC 1,67 167 67 (1,6 (PaO2 4.4 44 -4.4 9 8.3 83 3 -8. 06 0.6 6 -0.63 4.5 45 5 -4.5 8.8 01 0.1 -0.18 1,6 16 (1, (PaO 4. -4. 8. -8 0. -0.6 -0.1 1, (1 -4 - -0. ( -0

ABSTRACT BACKGROUND: Tocilizumab is an anti-human interleukin 6 receptor monoclonal antibody that has been used to treat coronavirus disease 2019 (COVID-19). However, there is no consensus on its efficacy for the treatment of COVID-19. OBJECTIVE: To evaluate the effectiveness and safety of tocilizumab for treating COVID-19. DESIGN AND SETTING: Systematic Review of randomized controlled trials (RCTs), Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil. METHODS: We searched MEDLINE via PubMed, EMBASE, CENTRAL, and IBECS for RCTs published up to March 2021. Two authors selected studies and assessed the risk of bias and the certainty of the evidence following Cochrane Recommendations. RESULTS: Eight RCTs with 6,139 participants were included. We were not able to find differences between using tocilizumab compared to standard care on mortality in hospitalized patients with COVID-19 (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.84 to 1.13; 8 trials; 5,950 participants; low-certainty evidence). However, hospitalized patients under tocilizumab plus standard care treatment seemed to present a significantly lower risk of needing mechanical ventilation (risk ratio = 0.78; 95% CI 0.64−0.94 moderate-certainty of evidence). CONCLUSIONS: To date, the best evidence available shows no difference between using tocilizumab plus standard care compared to standard care alone for reducing mortality in patients with COVID-19. However, as a finding with a practical implication, the use of tocilizumab in association to standard care probably reduces the risk of progressing to mechanical ventilation in those patients. REGISTRATION: osf.io/qe4fs. BACKGROUND antihuman anti human 201 COVID19. COVID19 COVID 19 . (COVID-19) However 19. OBJECTIVE SETTING RCTs, , (RCTs) UNIFESP, UNIFESP (UNIFESP) SP, SP (SP) Brazil METHODS PubMed EMBASE CENTRAL 2021 Recommendations RESULTS 6139 139 6,13 included COVID-1 RR (RR 097 0 97 0.97 95 (CI 084 84 0.8 1.13 113 1 13 5950 5 950 5,95 lowcertainty low evidence. evidence) 0.78 078 78 064094 64 94 0.64−0.9 moderatecertainty moderate CONCLUSIONS date implication REGISTRATION osfioqe4fs osfioqefs osf io qe4fs qe fs osf.io/qe4fs 20 COVID1 (COVID-19 (RCTs (UNIFESP (SP 202 613 6,1 COVID- 09 9 0.9 08 0. 1.1 11 595 5,9 0.7 07 7 06409 0.64−0. osfioqe qefs 2 (COVID-1 61 6, 1. 59 5, 0640 0.64−0 (COVID- 064 0.64− (COVID 06 0.64 0.6

Abstract Objective: To identify and assess the current evidence available about the costs of managing hospitalized pediatric patients diagnosed with Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in upper-middle-income countries. Methods: The authors conducted a systematic review across seven key databases from database inception to July 2022. Costs extracted were converted into 2022 International Dollars using the Purchasing Power Parity-adjusted. PROSPERO identifier: CRD42020225757. Results: No eligible study for PIV3 was recovered. For RSV, cost analysis and COI studies were performed for populations in Colombia, China, Malaysia, and Mexico. Comparing the total economic impact, the lowest cost per patient at the pediatric ward was observed in Malaysia ($ 347.60), while the highest was in Colombia ($ 709.66). On the other hand, at pediatric ICU, the lowest cost was observed in China ($ 1068.26), while the highest was in Mexico ($ 3815.56). Although there is no consensus on the major cost driver, all included studies described that the medications (treatment) consumed over 30% of the total cost. A high rate of inappropriate prescription drugs was observed. Conclusion: The present study highlighted how RSV infection represents a substantial economic burden to health care systems and to society. The findings of the included studies suggest a possible association between baseline risk status and expenditures. Moreover, it was observed that an important amount of the cost is destinated to treatments that have no evidence or support in most clinical practice guidelines. Objective (RSV PIV (PIV3 uppermiddleincome upper middle income countries Methods 202 Parityadjusted. Parityadjusted Parity adjusted. adjusted Parity-adjusted identifier CRD42020225757 CRD Results recovered impact $ ( 347.60, 34760 347.60 , 347 60 347.60) 709.66. 70966 709.66 . 709 66 709.66) hand ICU 1068.26, 106826 1068.26 1068 26 1068.26) 3815.56. 381556 3815.56 3815 56 3815.56) driver treatment (treatment 30 Conclusion society expenditures Moreover guidelines (PIV 20 CRD4202022575 3476 347.6 34 6 7096 709.6 70 10682 1068.2 106 2 38155 3815.5 381 5 CRD420202257 347. 709. 7 1068. 10 3815. 38 CRD42020225 1 CRD4202022 CRD420202 CRD42020 CRD4202 CRD420 CRD42 CRD4

Resumo O objetivo deste artigo é identificar a prevalência e os fatores associados à obesidade abdominal dinapênica (OAD) em idosos de uma cidade da região Norte do Brasil. Estudo transversal realizado com 382 idosos comunitários residentes em Macapá, Amapá, Brasil. As informações socioeconômicas, clínicas e de saúde foram coletadas por meio de um formulário estruturado. A OAD foi definida pela combinação de dinapenia (força de preensão manual < 26 kgf para homens e < 16 kgf para mulheres) e obesidade abdominal (circunferência abdominal > 102 cm para homens e > 88 cm para mulheres). As análises descritivas e inferenciais foram realizadas utilizando os testes qui-quadrado, t de Student e regressão de Poisson. A prevalência de OAD foi de 10,73%. Na análise bivariada preliminar, as variáveis faixa etária, estado conjugal, número de doenças, incapacidade funcional para atividades básicas e instrumentais de vida diária, velocidade da marcha e nível de atividade física atenderam ao critério estabelecido. O modelo final indicou que apenas a velocidade da marcha foi um preditor para a OAD em idosos. A OAD afeta quase 11% dos idosos residentes nessa comunidade do Norte do Brasil; e a velocidade de marcha é um preditor que pode ser uma ferramenta útil para gerenciar e monitorar a saúde desta população.

Abstract This article aims to identify the prevalence of and factors associated with dynapenic abdominal obesity (DAO) in older adults in a city in the northern region of Brazil. A cross-sectional study was conducted with 382 community-dwelling older adults in Macapa, Amapa, Brazil. Socioeconomic, clinical, and health information were collected using a structured form. DAO was defined as a combination of dynapenia (handgrip strength of < 26 kgf for men and < 16 kgf for women) and abdominal obesity (abdominal circumference > 102 cm for men and > 88 cm for women). Descriptive and inferential analyses were performed using chi-squared tests, Student’s t-tests, and a Poisson regression. The prevalence of DAO was 10.73%. In the preliminary bivariate analysis, the variables of age range, marital status, number of diseases, functional disability for basic and instrumental activities of daily living, gait speed, and level of physical activity met the established criterion. The final model indicated that only gait speed was a predictor of DAO in older adults. DAO affects nearly 11% of community-dwelling older adults from northern Brazil; gait speed was a predictor of DAO and could be a useful tool for managing and monitoring this population’s health.

Abstract Sjogren's syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration of the exocrine glands and other organs, associated with sicca syndrome but also with systemic involvement with varying degrees of severity. Despite their importance, some systemic manifestations, mainly liver, gastrointestinal, and pancreatic are not routinely evaluated. To address these manifestations, the Sjögren's Syndrome Committee of the Brazilian Society of Rheumatology conducted a broad systematic review of the literature on studies investigating prevalence and diagnosis of these symptoms in Sjogren´s patients and made recommendations based on the findings. Agreement between the experts was achieved using the Delphi method. This is the second part of this guideline, providing 6 recommendations for liver, gastrointestinal, and pancreatic care of SS patients.

Resumo O objetivo deste artigo é identificar a prevalência e os fatores associados à obesidade abdominal dinapênica (OAD) em idosos de uma cidade da região Norte do Brasil. Estudo transversal realizado com 382 idosos comunitários residentes em Macapá, Amapá, Brasil. As informações socioeconômicas, clínicas e de saúde foram coletadas por meio de um formulário estruturado. A OAD foi definida pela combinação de dinapenia (força de preensão manual < 26 kgf para homens e < 16 kgf para mulheres) e obesidade abdominal (circunferência abdominal > 102 cm para homens e > 88 cm para mulheres). As análises descritivas e inferenciais foram realizadas utilizando os testes qui-quadrado, t de Student e regressão de Poisson. A prevalência de OAD foi de 10,73%. Na análise bivariada preliminar, as variáveis faixa etária, estado conjugal, número de doenças, incapacidade funcional para atividades básicas e instrumentais de vida diária, velocidade da marcha e nível de atividade física atenderam ao critério estabelecido. O modelo final indicou que apenas a velocidade da marcha foi um preditor para a OAD em idosos. A OAD afeta quase 11% dos idosos residentes nessa comunidade do Norte do Brasil; e a velocidade de marcha é um preditor que pode ser uma ferramenta útil para gerenciar e monitorar a saúde desta população.

Abstract This article aims to identify the prevalence of and factors associated with dynapenic abdominal obesity (DAO) in older adults in a city in the northern region of Brazil. A cross-sectional study was conducted with 382 community-dwelling older adults in Macapa, Amapa, Brazil. Socioeconomic, clinical, and health information were collected using a structured form. DAO was defined as a combination of dynapenia (handgrip strength of < 26 kgf for men and < 16 kgf for women) and abdominal obesity (abdominal circumference > 102 cm for men and > 88 cm for women). Descriptive and inferential analyses were performed using chi-squared tests, Student’s t-tests, and a Poisson regression. The prevalence of DAO was 10.73%. In the preliminary bivariate analysis, the variables of age range, marital status, number of diseases, functional disability for basic and instrumental activities of daily living, gait speed, and level of physical activity met the established criterion. The final model indicated that only gait speed was a predictor of DAO in older adults. DAO affects nearly 11% of community-dwelling older adults from northern Brazil; gait speed was a predictor of DAO and could be a useful tool for managing and monitoring this population’s health.

Abstract Sjogren’s Syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration of the exocrine glands and other organs, associated with sicca syndrome but also with systemic involvement with varying degrees of severity. Despite their importance, these systemic manifestations are not routinely evaluated and there is no homogenous approach to their diagnosis or evaluation. To close this gap, a panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis on the identification of epidemiologic and clinical features of these manifestations and made recommendations based on the findings. Agreement between the experts was achieved using the Delphi method. The first part of this guideline summarizes the most important topics, and 11 recommendations are provided for the articular, pulmonary, and renal care of SS patients.

ABSTRACT BACKGROUND: Tocilizumab is an anti-human interleukin 6 receptor monoclonal antibody that has been used to treat coronavirus disease 2019 (COVID-19). However, there is no consensus on its efficacy for the treatment of COVID-19. OBJECTIVE: To evaluate the effectiveness and safety of tocilizumab for treating COVID-19. DESIGN AND SETTING: Systematic Review of randomized controlled trials (RCTs), Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil. METHODS: We searched MEDLINE via PubMed, EMBASE, CENTRAL, and IBECS for RCTs published up to March 2021. Two authors selected studies and assessed the risk of bias and the certainty of the evidence following Cochrane Recommendations. RESULTS: Eight RCTs with 6,139 participants were included. We were not able to find differences between using tocilizumab compared to standard care on mortality in hospitalized patients with COVID-19 (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.84 to 1.13; 8 trials; 5,950 participants; low-certainty evidence). However, hospitalized patients under tocilizumab plus standard care treatment seemed to present a significantly lower risk of needing mechanical ventilation (risk ratio = 0.78; 95% CI 0.64−0.94 moderate-certainty of evidence). CONCLUSIONS: To date, the best evidence available shows no difference between using tocilizumab plus standard care compared to standard care alone for reducing mortality in patients with COVID-19. However, as a finding with a practical implication, the use of tocilizumab in association to standard care probably reduces the risk of progressing to mechanical ventilation in those patients. REGISTRATION: osf.io/qe4fs.

ABSTRACT BACKGROUND: Existence of an association between sedentary behavior and frailty among older adults has been suggested. However, there is a lack of studies conducted in Brazil, especially in areas of the Amazon region. OBJECTIVE: To analyze the association between frailty syndrome and sedentary behavior among community-dwelling older adults. DESIGN AND SETTING: Cross-sectional study carried out in Macapá, state of Amapá, Brazil. METHODS: Frailty status was assessed using Fried's frailty phenotype, and sedentary behavior was evaluated using two questions concerning time spent in a seated position, from the International Physical Activity Questionnaire (IPAQ). A multinomial logistic regression model was used to verify the association between frailty syndrome and sedentary behavior. RESULTS: The final study sample was made up of 411 older adults with a mean age of 70.14 ± 7.25 years and an average daily duration of sedentary behavior of 2.86 ± 2.53 hours. The prevalence of non-frailty was 28.7%, prevalence of pre-frailty was 58.4% and prevalence of frailty was 12.9%. The adjusted analysis showed that there were independent associations between sedentary behavior and pre-frailty (odds ratio, OR = 1.18; 95% confidence interval, CI: 1.03-1.34) and between sedentary behavior and frailty (OR = 1.20; 95% CI: 1.02-1.40). CONCLUSION: Frailty and pre-frailty status were associated with sedentary behavior among community-dwelling older adults.

Abstract INTRODUCTION: Psychosocial aspects need to be discussed in the context of the Covid-19 pandemic. Currently, no studies have investigated the factors associated with social isolation and loneliness among community-dwelling older adults. Therefore, this study analyzed the association of social isolation and loneliness with socioeconomic, clinical, and health characteristics, and Covid-19-related variables, among community-dwelling older adults during the pandemic. METHODS: A cross-sectional study was conducted via a telephone survey of community-dwelling older adults aged ≥60 years in Macapa, Amapa, Brazil. A structured form was used to collect data. Descriptive and inferential analyses were performed using Pearson's correlation test and a linear regression model. RESULTS: Participants comprised 86 community-dwelling older adults with a mean age of 71.78+6.98 years. Among them, 9.3% were diagnosed with Covid-19, of whom 3.5% were hospitalized. Most participants reported no difficulty obtaining food, medicines, or attending routine medical appointments during the pandemic. Furthermore, 23.3% (n=20) were socially isolated, and 20.9% (n=18) reported feelings of loneliness. The mean values for fear, anxiety, and obsession were 19.01±7.25, 1.01±1.90, and 2.84±3.28, respectively. A moderate positive correlation was identified between loneliness and the number of diseases, and a weak positive correlation between loneliness and the number of medications and depressive symptoms and risk for sarcopenia. The linear regression model indicated that higher loneliness scores were associated with a greater number of diseases (β=0.288; p=0.007). CONCLUSIONS: The findings suggest a probable resilience of the older population to Covid-19, despite the association of loneliness with many diseases in times of a pandemic.

Abstract Sjogren’s syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration of the exocrine glands and other organs. Women with SS often experience gynecological symptoms due to the disease and need extra care regarding their sexual activity, reproductive health and during pregnancy, conditions that are not properly conducted in the clinical practice. To cover this gap, a panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis on the identification of symptoms, diagnosis, monitoring, prognosis, and treatment of these manifestations. A Focus Group meeting was held and included experts in the field and methodologists, based on a previously developed script, with themes related to the objective of the study. The most important topics were summarized and 11 recommendations were provided.

Resumo Objetivo O objetivo deste estudo foi comparar a qualidade de vida entre idosos sarcopênicos e não sarcopênicos e verificar a associação entre sarcopenia e qualidade de vida em idosos residentes na comunidade. Métodos Estudo transversal conduzido com idosos residentes na comunidade (n = 378) de Macapá, Amapá, Brasil. A qualidade de vida foi avaliada por meio do Short Form (36) Health Survey. O algoritmo proposto pelo Grupo de Trabalho Europeu sobre Sarcopenia em Pessoas Idosas (EWGSOP) foi usado para avaliar a sarcopenia. Foram realizadas análises descritivas, inferenciais e modelo de regressão linear. Resultados Os idosos sarcopênicos apresentaram escores de qualidade de vida significativamente mais baixos nos domínios função física, dor corporal, estado geral de saúde e função social. Após o ajuste, a sarcopenia associou-se inversamente ao funcionamento físico (β = -0,125; p = 0,010) e ao estado geral de saúde (β = -0,112; p = 0,028). Conclusão Os resultados deste estudo sugerem um provável declínio na qualidade de vida em idosos sarcopênicos, principalmente nos domínios funcionamento físico e estado geral de saúde.

Abstract Objective This study aimed to compare quality of life between sarcopenic and non-sarcopenic older adults and to verify the association of sarcopenia and quality of life in community-dwelling older adults. Methods This was a cross-sectional study conducted in community-dwelling older adults (n = 378) from Macapá, Amapá, Brazil. Quality of life was assessed using the Short Form (36) Health Survey. The algorithm proposed by the European Working Group on Sarcopenia in Older People (EWGSOP) was used to assess sarcopenia. Descriptive, inferential analyses and linear regression model were performed. Results Sarcopenic older adults presented significantly lower quality of life scores in the domains of physical functioning, bodily pain, general health status, and social functioning. After adjustment, sarcopenia was inversely associated with physical functioning (β = -0.125; p = 0.010) and general health status (β = -0.112; p = 0.028). Conclusion The results of this study suggest a probable decline in the quality of life in sarcopenic older adults, especially in the physical functioning and general health status domains.

Resumen Objetivo El objetivo de este estudio fue comparar la calidad de vida entre adultos mayores con sarcopenia y sin sarcopenia y verificar la relación entre sarcopenia y calidad de vida en adultos mayores residentes de la comunidad. Métodos Estudio transversal llevado a cabo con adultos mayores residentes de la comunidad (n = 378) de Macapá, estado de Amapá, Brasil. La calidad de vida fue evaluada mediante el Short Form (36) Health Survey. El algoritmo propuesto por el Grupo Europeo de Trabajo sobre la Sarcopenia en Personas de Edad Avanzada (EWGSOP) fue utilizado para evaluar la sarcopenia. Se realizaron análisis descriptivos, inferenciales y modelo de regresión lineal. Resultados Los adultos mayores con sarcopenia presentaron una puntuación de calidad de vida significativamente más baja en los dominios función física, dolor corporal, estado general de salud y función social. Luego del ajuste, la sarcopenia se relacionó inversamente con el funcionamiento físico (β = -0,125; p = 0,010) y con el estado general de salud (β = -0,112; p = 0,028). Conclusión Los resultados de este estudio sugieren un probable deterioro en la calidad de vida de adultos mayores con sarcopenia, principalmente en los dominios funcionamiento físico y estado general de salud.

RESUMO O objetivo desta revisão sistemática foi identificar as barreiras e facilitadores para a implementação da mobilização precoce em unidades de terapia intensiva pediátrica. Realizou-se uma busca sistemática baseada em estudos que abordassem barreiras e/ou facilitadores para mobilização precoce em crianças e adolescentes. Foram incluídos estudos publicados até junho de 2019 nas bases de dados MEDLINE®, Physiotherapy Evidence Database, Literatura Latino-Americana e do Caribe em Ciências da Saúde, Cochrane Library, Scientific Electronic Library Online. A seleção e a avaliação da qualidade metodológica foram realizadas por dois revisores independentes. Dados que pudessem ser identificados como barreiras e/ou facilitadores foram extraídos para análise. Foram encontrados 358 registros nas bases de dados, dos quais foram incluídos 13 artigos. Foram citadas 18 barreiras, sendo as mais citadas o número insuficiente de profissionais, e insegurança da equipe. Dos 11 facilitadores citados, os mais frequentes foram treinamento/educação da equipe multidisciplinar e a instituição de diretriz/consenso. Existem muitas barreiras a serem quebradas para que a mobilização precoce seja efetiva, porém alguns facilitadores já são conhecidos e podem ser implementados, tornando viável a sua implementação para a população pediátrica.

ABSTRACT This systematic review aimed to identify barriers and facilitators for the implementation of early mobilization in pediatric intensive care units. A systematic search was carried out based on studies that addressed barriers and/or facilitators for early mobilization in children and adolescents. Studies published until June 2019 in the MEDLINE®, Physiotherapy Evidence Database, Latin American & Caribbean Health Sciences Literature, Cochrane Library, and Scientific Electronic Library Online databases were included. Selection and assessment of methodological quality were performed by two independent reviewers. Data that could be identified as barriers and/or facilitators were extracted for analysis. 358 records were found in the databases, of which 13 articles were included. 18 barriers were cited; the most cited ones were the insufficient number of professionals and team’s insecurity. Of the 11 mentioned facilitators, the most frequent were training/education of the multidisciplinary team and the establishment of guidelines/consensus. There are many barriers to be broken for early mobilization to be effective, but some facilitators are already known and can be implemented, making their implementation feasible for the pediatric population.

RESUMEN El propósito de esta revisión sistemática fue identificar barreras y facilitadores para aplicar la movilización temprana en las unidades de cuidados intensivos pediátrica. Se realizó una búsqueda sistemática de estudios que abordaron barreras y/o facilitadores para la movilización temprana en niños y adolescentes. Se incluyeron estudios publicados hasta junio de 2019 en las bases de datos MEDLINE®, Physiotherapy Evidence Database, Literatura Latinoamericana y del Caribe en Ciencias de la Salud, Cochrane Library y Scientific Electronic Library Online. La selección y evaluación de la calidad metodológica fue realizada por dos revisores independientes. Los datos que se han identificado como barreras y/o facilitadores se extrajeron para su análisis. De los 358 registros encontrados en las bases de datos, se incluyeron 13 artículos. Se mencionaron 18 barreras, y las más citadas fueron el número insuficiente de profesionales y la inseguridad del equipo. De los 11 facilitadores mencionados, los más frecuentes fueron la formación/educación del equipo multidisciplinario y el establecimiento de lineamientos/consensos. Hay muchas barreras que romper para que la movilización temprana sea efectiva, pero algunos facilitadores ya son conocidos y pueden ser aplicados, haciendo su aplicación factible a la población pediátrica.

ABSTRACT BACKGROUND: Patients with immune-mediated inflammatory diseases (IMID) are at increased risk of infection. OBJECTIVE: To assess whether patients undergoing pharmacological treatment for IMID present higher risk of worse outcomes when diagnosed with COVID-19. DESIGN AND SETTING: Rapid systematic review conducted in the medical school of the Federal University of São Paulo (SP), Brazil. METHODS: We searched CENTRAL, MEDLINE, EMBASE, LILACS, SCOPUS, Web of Science, L·OVE, ClinicalTrials.gov and WHO-ICTRP for studies evaluating patients diagnosed with COVID-19 who were undergoing pharmacological treatment for IMID. Two authors selected studies, extracted data and assessed risk of bias and certainty of evidence, following the Cochrane recommendations. RESULTS: We identified 1,498 references, from which one cohort study was included. This compared patients with and without rheumatic diseases (RD) who all had been diagnosed with COVID-19. Those with RD seemed to have higher chances of hospitalization and mortality, but no statistical difference was detected between the groups: hospitalization: odds ratio (OR) 1.17; 95% confidence interval (CI) 0.6 to 2.29; mortality rate: OR 1.53; 95% CI 0.33 to 7.11 (very low certainty of evidence). Patients with RD were three times more likely to require admission to intensive care units (ICUs), with invasive mechanical ventilation (IMV), than those without RD: OR 3.72; 95% CI 1.35 to 10.26 (for both outcomes; very low certainty of evidence). CONCLUSION: Patients undergoing pharmacological treatment for IMID seem to present higher chances of requiring admission to ICUs, with IMV. Additional high-quality studies are needed to analyze the effects of different treatments for IMID.